UNSPSC 51334004: Tiospirone

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C24H32N4O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45Q1DF53NN, chemically known as 8-azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-, monohydrochloride but generally known as tiospirone hydrochloride, which bears US NIH Compound Identifier 55751. Most nations schedule tiospirone under HS 29349990 and SITC 51579. As of Q4 2014, TIOSPIRONE remains the US FDA Preferred Term for this commodity.

Tiospirone bears US NLM identifiers UMLS ID C0076710 and NCI Concept Code C73303. SMILES: C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54.Cl.

UNSPSC 51334004 Tiospirone is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged under this code address a broader range of pharmaceutical procurement including naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than tiospirone specifically. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work solicited ranges from direct purchase of specific pharmaceutical products for community health initiatives to cooperative contracting frameworks that establish supply relationships with manufacturers through authorized wholesalers and require compliance with FDA standards, cGMP certification, Drug Supply Chain Security Act requirements, and performance metrics tied to reporting and delivery timelines.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, with quarterly deliveries to the county community health building and vendor responsibility for all shipping costs. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling early-stage procurement development rather than a near-term award. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date; MMCAP evaluates proposals on price competitiveness (75 percent weight), fixed pricing (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and administrative format compliance (5 percent), and awards are not disclosed by dollar value.